-5 - Novel use of C-terminal domain of IGFBP-5 comprising heparin-binding domain as an angiogenesis inhibitor

摘要

The present invention relates to a pharmaceutical composition for inhibiting angiogenesis, which comprises, as an active ingredient, a peptide comprising heparin-binding domain of IGFBP-5 (insulin-like growth factor-binding protein 5) A method for inhibiting angiogenesis, a pharmaceutical composition for preventing or treating cancer comprising the peptide as an active ingredient, a method for treating cancer using the peptide, a novel angiogenesis derived from the heparin-binding domain of IGFBP-5 Inhibitory peptides, polynucleotides encoding the peptides, vectors containing the polynucleotides, and transformants containing the vectors.